Vepugratinib

DRUG3 trials

Sponsors

Eli Lilly and Company

Conditions

Carcinoma, Transitional CellNeoplasm MetastasisUreteral NeoplasmsUrinary Bladder Neoplasms

Phase 1

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

RecruitingNCT05614739

Eli Lilly and CompanyUrinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms

Start: 2023-01-12End: 2027-06-01Target: 677Updated: 2026-08-20

Phase 3

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

RecruitingNCT07218380

Eli Lilly and CompanyCarcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis

Start: 2025-12-12End: 2033-05-01Target: 450Updated: 2026-08-21

Unknown Phase

Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors

Eli Lilly and CompanyUrinary Bladder Neoplasms, Neoplasm Metastasis, Carcinoma, Transitional Cell

Updated: 2026-06-30

Related Papers

Abstract A090: Vepugratinib (LY3866288), a potent highly isoform-selective FGFR3 inhibitor, enhances the activity of enfortumab vedotin (EV) in FGFR3-altered metastatic urothelial cancer (mUC) models

Molecular Cancer Therapeutics2025-10-22

A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with <i>FGFR3</i> alterations: Initial results from FORAGER-1.

Journal of Clinical Oncology2025-02-1010 citations

A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

Cancer Research Communications2024-04-1116 citations

Development of a novel RNA-based fibroblast growth factor receptor response signature (FGFR-PRS) for use in patients with urothelial cancer (UC).

Journal of Clinical Oncology2024-01-29

Abstract CT119: A first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with <i>FGFR3</i> alterations (trial in progress)

Cancer Research2023-04-149 citations